^
    Back
    Association details:
    Biomarker:EML4-ALK fusion
    Cancer:Ovarian Cancer
    Drug:Alecensa (alectinib) (ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    Source:
    Jpn J Clin Oncol
    Title:

    EML4-ALK, a potential therapeutic target that responds to alectinib in ovarian cancer

    Published date:
    08/26/2020
    Excerpt:
    Here, we present a patient with metastatic ALK+ high-grade serous ovarian cancer that testing positive for EML4-ALK (microtubule-associated protein-like 4 gene, fused to the anaplastic lymphoma kinase gene), experienced dramatic benefit after administration of the anaplastic lymphoma kinase inhibitor alectinib.
    DOI:
    10.1093/jjco/hyaa156